Published On: Wed, Oct 19th, 2016

Analyst Review: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)


A number of investment brokers have recently updated their price targets on shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX).

Most recent broker ratings

10/17/2016 – Lexicon Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 26 price target on the stock.

09/15/2016 – Lexicon Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Wedbush. They now have a USD 33 price target on the stock.

09/12/2016 – Lexicon Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Citigroup. They now have a USD 25 price target on the stock.

09/09/2016 – Lexicon Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Needham & Company. They now have a USD 21 price target on the stock.

05/06/2016 – Cowen began new coverage on Lexicon Pharmaceuticals, Inc. giving the company a “market perform” rating.

09/28/2015 – Lexicon Pharmaceuticals, Inc. was upgraded to “hold” by analysts at Gabelli. They now have a USD 13.5 price target on the stock.

08/10/2015 – Lexicon Pharmaceuticals, Inc. was downgraded to “neutral” by analysts at JP Morgan. They now have a USD 14 price target on the stock.

05/01/2015 – Lexicon Pharmaceuticals, Inc. had its “hold” rating reiterated by analysts at Zacks.

03/05/2015 – Lexicon Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Stifel Nicolaus. They now have a USD 3 price target on the stock.

12/24/2013 – Lexicon Pharmaceuticals, Inc. was downgraded to “sell” by analysts at Thomson Reuters/Verus.

12/06/2013 – Bank of America Merrill Lynch began new coverage on Lexicon Pharmaceuticals, Inc. giving the company a “underperform” rating. They now have a USD 1.5 price target on the stock.

The share price of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) was up +1.57% during the last day of trading, with a day high of 16.92. 833639 shares were traded during the last session.

The stock’s 50 day moving average is 17.50 and its 200 day moving average is 15.11. The stock’s market capitalization is 1.74B. Lexicon Pharmaceuticals, Inc. has a 52-week low of 7.65 and a 52-week high of 19.62.

Lexicon Pharmaceuticals, Inc. (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome. LX1032 inhibits tryptophan hydroxylase (TPH), which is an orally-delivered small molecule compound that the Company is developing for the treatment of carcinoid syndrome. Sotagliflozin, or LX4211, which is an orally-delivered small molecule compound that the Company is developing for the treatment of type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound for the treatment of neuropathic pain. The Company’s other programs include LX1033, LX2931 and LX7101.